Emerging Therapeutic Potential of Mesenchymal Stem/Stromal Cells in Preeclampsia

Sonja Suvakov, C Richards, Valentina Nikolic, Tatjana P Simic, K McGrath, Anna Krasnodembskaya, Lana McClements*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)
387 Downloads (Pure)


Purpose of Review

Preeclampsia is a dangerous pregnancy condition affecting both the mother and offspring. It is a multifactorial disease with poorly understood pathogenesis, lacking effective treatments. Maternal immune response, inflammation and oxidative stress leading to endothelial dysfunction are the most prominent pathogenic processes implicated in preeclampsia development. Here, we give a detailed overview of the therapeutic applications and mechanisms of mesenchymal stem/stromal cells (MSCs) as a potential new treatment for preeclampsia.
Recent Findings

MSCs have gained growing attention due to low immunogenicity, easy cultivation and expansion in vitro. Accumulating evidence now suggests that MSCs act primarily through their secretomes facilitating paracrine signalling that leads to potent immunomodulatory, pro-angiogenic and regenerative therapeutic effects.

MSCs have been studied in different animal models of preeclampsia demonstrating promising result, which support further investigations into the therapeutic effects and mechanisms of MSC-based therapies in preeclampsia, steering these therapies into clinical trials.
Original languageEnglish
Article number37
JournalCurrent Hypertension Reports
Publication statusPublished - 14 Apr 2020


Dive into the research topics of 'Emerging Therapeutic Potential of Mesenchymal Stem/Stromal Cells in Preeclampsia'. Together they form a unique fingerprint.

Cite this